Viewing StudyNCT00113360

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-05 @ 11:44 AM
Last Modification Date: 2024-10-26 @ 9:12 AM
Study NCT ID: NCT00113360
Status: COMPLETED
Last Update Posted: 2023-10-25
First Post: 2005-06-07
Brief Title: RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
Sponsor: MD Anderson Cancer Center
Organization: MD Anderson Cancer Center
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Islet Cell Carcinoma
Neuroendocrine Carcinoma
Keywords:
Name View
Octreotide LAR View
Neuroendocrine Carcinoma View
Low Grade Neuroendocrine Carcinoma View
Neuroendocrine Carcinoid View
Islet Cell Carcinoma View
RAD001 View
Everolimus View
Octreotide Depot View
Sandostatin LAR View
Octreotide long-acting release LAR View